Microbio Group Achieves Another Milestone in Corporate Governance Evaluation
Microbio and Oneness Rank Among Top 5% in the Corporate Governance Evaluation for Five Consecutive Years; Diamond Biofund Secures Top 5% for 2nd Year
The results of the 12th Corporate Governance Evaluation (2025) were officially announced on April 30. Microbio Group once again delivered outstanding results, with the three listed companies under Microbio Group receiving top-tier recognition. Microbio Co., Ltd. (4128) and Oneness Biotech Co Ltd. (4743) have both been ranked among the Top 5% of TPEx-listed companies for five consecutive years, maintaining their benchmark status in Corporate Governance. Diamond Biofund Inc. (6901), following its first-time evaluation last year with a Top 5% ranking among listed companies, has once again attained the Top 5% distinction. In addition, both Oneness and Diamond Biofund were ranked in the top 10% of non-financial and non- electronics industry with a market value of TWD 10 billion or more, showcasing the Microbio Group’s outstanding achievements in corporate governance and sustainable development.
The Corporate Governance Evaluation is conducted annually by the Taiwan Stock Exchange (TWSE) and Taipei Exchange (TPEx), comprehensively assessing listed companies on their governance and sustainability performance. This year, 1009 TWSE-listed and 801 TPEx-listed companies were evaluated. Being ranked in the top 5% represents the highest recognition in the evaluation.
Dr. Tzen-Wen Chen, Chairman of Microbio Co., Ltd., stated that the company has been steadily advancing ESG initiatives from the top down. Over the past two years, Microbio has further expanded sustainability information disclosure and implementation to its subsidiaries, including Cotton Field Organic Co., Ltd. and Microbio (Shanghai) Co., Ltd.. Key actions include the adoption of IFRS Sustainability Disclosure Standards, electricity monitoring for high-energy-consuming equipment, energy efficiency improvements at logistics centers, and comprehensive packaging management programs. These efforts reflect Microbio Group’s commitment to its vision of “Healthy Lifestyles, Sustainable Prosperity for All.” The R&D and Sales teams continue to leverage the Symbiota core technology platform to expand markets through diversified business models, transforming technological value into long-term growth momentum. Being ranked in the Top 5% for five consecutive evaluations is not only an honor but also a strong recognition of the team’s dedication to ESG.
Dr. Hsien-Shou Kuo, Chairman of Oneness Biotech Co Ltd., stated that since its founding, Oneness has consistently regarded “Ethical Governance” and “Innovation and R&D” as the dual engines driving its global competitiveness. Repeatedly earning a Top 5% ranking in the Corporate Governance Evaluation demonstrates the company’s high level of transparency and robust practices in safeguarding shareholder rights and enhancing board functions. Built on a solid governance foundation, Oneness continues to advance its global business development strategy by enabling worldwide access to its innovative products, addressing unmet medical needs, and promoting healthcare equity. In the future, Oneness will continue to leverage outstanding governance performance to drive business growth and progress toward becoming an international sustainability benchmark enterprise.
Dr. Pan-Chyr Yang, Chairman of Diamond Biofund, stated that the Company’s consecutive Top 5% ranking underscores the maturity of its sustainable governance. By integrating “Responsible Investment Policy” into post-investment engagement, Diamond Biofund is spearheading the biotechnology industry’s transformation. In 2025, the Company will further bolster operational resilience and long-term value by transitioning to renewable energy to achieve low-carbon operations, aligning sustainability with financial governance. The Company’s inclusion in the 2026 S&P Global Sustainability Yearbook and its Top 10% ranking in the Diversified Financial Services and Capital Markets industry demonstrate that Diamond Biofund has established global competitiveness in governance and sustainability.
Microbio Group is a leading force in Taiwan’s biotechnology industry, with operations spanning new drug and medical device, health product research and sales, biotechnology investment, and organic businesses. Microbio Group remains focused on its core competencies while continuously enhancing corporate value. It is also committed to corporate social responsibility, actively promoting environmental sustainability and social prosperity.
